/
Oncology
Cholangiocarcinoma
85
Pipeline Programs↗
95
Active Trials↗
46
Companies Involved↗
Cholangiocarcinoma is a moderately active landscape with 85 programs across 46 companies. The most active players are Roche, Cogent Biosciences, Inc., Eli Lilly. 18 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical19
Phase 14
Phase 244
Phase 318
Approved
No programs
Analysis
Modality Breakdown
72%
Small molecule
59 of 82 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 82 classified programs, each share of the total. Modality classified for 98% of 85 pipeline programs.
Analysis
Trial Status
231
clinical trials
Recruiting57 · 25%
Completed54 · 23%
Unknown status40 · 17%
Terminated27 · 12%
Not yet recruiting20 · 9%
Active, not recruiting17 · 7%
Other16 · 7%
Clinical Trials
Trial Activity
231 trials
A Phase II Study of Pemigatinib Plus Durvalumab (MEDI4736) in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Recruiting·—·Phase 2·NCT06728410·38 enrolled
Protective Mechanisms of Phycocyanin in Partial Hepatectomy-Associated Liver Injury
Recruiting·Second Affiliated Hospital, Zhejiang University, School of Medicine·Preclinical·NCT07760038·30 enrolled
Page 1 of 16
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)